Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010
Cited by 2,144 works. doi:10.1016/s1470-2045(10)70130-3
Authors
- Wendy De Roock
- Bart Claes
- David Bernasconi
- Jef De Schutter
- Bart Biesmans
- George Fountzilas
- Konstantine T. Kalogeras
- Vassiliki Kotoula
- Demetris Papamichael
- Pierre Laurent‐Puig
- Frederique Madeleine Penault-Llorca
- Philippe R Rougier
- Bruno Vincenzi
- Daniele Santini
- Giuseppe Tonini
- Federico Cappuzzo
- Milo Frattini
- Francesca Molinari
- Piercarlo Saletti
- Sara De Dosso
References
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
- K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- Unbiased Recursive Partitioning: A Conditional Inference Framework
- Targeting RAS signalling pathways in cancer therapy
- Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer